Drug Profile
Research programme: antibacterials - Calmune Corporation
Alternative Names: CAL-301Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Calmune Corporation
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Klebsiella infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Klebsiella-infections in USA
- 30 Oct 2009 Early research in Klebsiella infections in USA (unspecified route)